Return to CAP Home

  CAP Begins Monitoring
  ER/PgR Performance

  e-Alert

Posted December 15, 2011

CAP Begins Monitoring ER/PgR Performance

The College of American Pathologists (CAP) announced, in 2010, a new requirement for participation in its Laboratory Accreditation Program (LAP) to ensure the quality of ER/PgR testing. This requirement was based on a new Guideline for estrogen and progesterone receptor (ER/PgR) Performance developed through a cooperative effort between the American Society of Clinical Oncology and the CAP.

  • In 2011: Laboratories performing ER/PgR by immunohistochemistry on primary breast cancers were required to enroll and participate in CAP-accepted proficiency testing.


  • In 2012: Laboratories performing ER/PgR on patient samples are required to enroll, participate and maintain successful performance in the PM2 Survey (or other CAP-accepted PT). The LAP will monitor ER/PgR proficiency testing performance.

If you have any questions, please contact a PT Compliance representative at 1-800-323-4040 ext. 6052 or 1-847-832-7000 ext. 6052.

If you would like to order the PM2 Survey, please call a Customer Contact Center representative at 1-800-323-4040, Option 1.

Thank you for your cooperation in implementing this important new quality program for estrogen and progesterone receptor testing and for your ongoing support of the CAP’s Laboratory Accreditation Program.